06 July 2016
Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today announced that it has entered into an exclusive worldwide license agreement with UCB for UCB6352, an IND-ready anti-CSF-1R monoclonal antibody, which is expected to begin clinical trials in 2016.
ReVision Optics Receives FDA Approval for the Raindrop® Near Vision Inlay
29 June 2016
ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces receipt of U.S. Food and Drug Administration (FDA) approval for the Raindrop® Near Vision Inlay, a novel corneal inlay for the surgical correction of presbyopia. The Raindrop Near Vision Inlay is indicated to improve near vision by reshaping the anterior curvature of the cornea in presbyopic patients who have emmetropic refractions (+1.00 D to -0.50 D).
28 June 2016
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced top-line data from a Phase 2 exploratory, investigator-sponsored study to evaluate the safety, tolerability and efficacy of ganaxolone for the treatment of anxiety and attention in children with Fragile X Syndrome (FXS). The investigator selected Clinical Global Impression of Improvement (CGI-I), which is a broad scale to assess the overall improvement across the entire Fragile X Syndrome, as the primary endpoint of the study.
Epic Sciences Introduces Sensitive HRD Liquid Biopsy Test for PARP Inhibitor Clinical Trials
24 June 2016
Epic Sciences unveiled a liquid biopsy test that more sensitively detects cancers susceptible to PARP inhibitors by targeting homologous recombination deficiency (HRD) in individual circulating tumor cells (CTCs). The new test has already been incorporated into numerous clinical studies of HRD-targeted therapeutics in multiple cancer types.
Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV
22 June 2016
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, tMarinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it has dosed the first subject in its Phase 1 clinical trial of ganaxolone IV, an intravenous (IV) formulation of Marinus' CNS-selective GABAA modulator, for the treatment of status epilepticus (SE).
09 June 2016
Miramar Labs, Inc., a global aesthetic company announced today that it has entered into an exclusive distribution agreement with Meheco, a state-holding company listed on the Shanghai Stock Exchange. Miramar Labs received the China Food and Drug Administration (CFDA) initial approval in May 2015 for the marketing and sale of miraDry® system in the People’s Republic of China and full approval to distribute its product in April 2016.
Miramar Labs, Inc. Completes Alternative Public Offering, Raises $9.0 Million
08 June 2016
Miramar Labs, Inc., announced today its successful completion of a reverse merger with Miramar Technologies, Inc., the manufacturers of the miraDry® system which delivers microwave energy to non-invasively destroy sweat and odor glands in the underarm. The combined entity will trade on the OTC Markets solely focusing on the business of Miramar and has applied for the ticker symbol “MIRA”.
04 June 2016
Detecting AR-V7 positive tumor cells circulating in the blood of an advanced prostate cancer patient predicts that he will not only fail the commonly-prescribed androgen receptor signaling inhibitors (ARSI), abiraterone and enzalutamide, but that he will survive significantly longer if treated with a taxane based chemotherapy regimen.
02 June 2016
Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the STI Point-Of-Care (POC) molecular diagnostics company, today notes the major issue of antibiotic resistance for Sexually Transmitted Infections (STIs), as highlighted in the UK Government commissioned anti-microbial resistance report, chaired by Jim O’Neill – ‘Tackling Drug-Resistant Infections Globally’ and recently referenced on the BBC program Newsnight. The O’Neill report recommends that in high income countries health system leaders should ‘support the uptake and use of rapid point-of care diagnostics in primary and secondary care.
Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering
01 June 2016
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of $7.00 per share.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024